Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 20;26(1):250.
doi: 10.1186/s12882-025-04177-1.

miRNAs in secondary hyperparathyroidism: literature review

Ziyi Lu  1 , Kexin Zhang  1 , Junyue Huang  2 , Shoukai Zhang  3
Affiliations
Review

miRNAs in secondary hyperparathyroidism: literature review

Ziyi Lu et al. BMC Nephrol. .

Abstract

Secondary hyperparathyroidism (SHPT) is a common complication of Chronic kidney disease (CKD), which is mainly manifested by the overproduction of Parathyroid hormone (PTH), leading to multi-system pathologies such as calcium and phosphorus metabolism disorders, skeletal lesions, and cardiovascular diseases, which seriously affects the quality of life of patients. In recent years, the role of microRNAs (miRNAs) in the pathogenesis of SHPT has been gradually revealed, providing new research directions for diagnosing and treating the disease. miRNAs play an important role in the development of SHPT by regulating genes related to calcium-phosphorus metabolism, influencing the stability and translational efficiency of PTH mRNAs, and regulating the proliferation and apoptosis of parathyroid cells. miRNA-based gene therapy strategies (e.g., miRNA antagonists or mimics) have shown promising therapeutic effects in animal models, but their clinical translation still faces challenges such as targeted delivery and safety. This review aims to summarize the mechanistic roles of miRNA and the progress of research in SHPT studies to provide a theoretical basis for diagnosing and treating SHPT.

Keywords: Gene therapy; Hyperparathyroidism; Secondary; miRNAs.

PubMed Disclaimer

Conflict of interest statement

Declarations. Consent to participate: Not applicable. Consent to publish: Not applicable. Competing interests: The authors declare no competing interests.

References

    1. Hassan A, Khalaily N, Kilav-Levin R, et al. Molecular mechanisms of parathyroid disorders in chronic kidney disease. Metabolites. 2022;12(2). - PMC - PubMed
    1. Zhang LX, Zhang B, Liu XY, et al. Advances in the treatment of secondary and tertiary hyperparathyroidism. Front Endocrinol (Lausanne). 2022;13:1059828. - PMC - PubMed
    1. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136(2):215–33. - PMC - PubMed
    1. Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6). - PMC - PubMed
    1. Corbetta S, Lania A, Filopanti M, Vicentini L, Ballaré E, Spada A. Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells. J Clin Endocrinol Metab. 2002;87(5):2201–5. - PubMed

MeSH terms

LinkOut - more resources